

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

VOLUNTARY ANNOUNCEMENT “PERAMIVIR INJECTION” APPROVED FOR MARKETING

The board (the “**Board**”) of directors (the “**Directors**”) of Fusen Pharmaceutical Company Limited (the “**Company**“, together with its subsidiaries, the “**Group**”) is pleased to announce that “Peramivir Injection” (帕拉米韋注射液), developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has obtained the approval for marketing from the National Medical Products Administration of the PRC* (國家藥品監督管理局) for the treatment of influenza A or B virus.

“Peramivir Injection” is the only anti-influenza injection approved by the United States Food and Drug Administration (FDA) and is the first neuraminidase inhibitor (NAI) approved in the PRC for intravenous administration in the treatment of influenza A and B viruses. It is indicated for severe influenza and for patients with Oseltamivir oral medication intolerance. It can rapidly reduce fever and relieve influenza-associated symptoms, such as nasal congestion, rhinorrhoea, expectorations, and cough.

Peramivir is a next-generation neuraminidase inhibitor that selectively inhibits the neuraminidase enzyme of the human influenza A and B viruses, preventing the release of mature virus particles from its host cells, thereby inhibiting viral spread within the human body and attaining successful treatment against influenza. Peramivir can be applied for the treatment of influenza A or B virus in patients of all age groups.

“Peramivir Injection” is a Class B drug under the National Healthcare Security Administration of the PRC. It is recommended for the treatment of influenza A or B virus by multiple guidelines and consensus in the PRC, including *the Chinese Guidelines for the Diagnosis and Treatment of Influenza* (《流行性感感冒診療方案》), *the Clinical Practice Guidelines for the Diagnosis and Treatment of Acute Upper Respiratory Tract Infection in Adults* (《成人普通感冒診斷和治療臨床實踐指南》), *the Expert Consensus on Antiviral Treatment of Influenza in Adults* (《成人流行性感感冒抗病毒治療專家共識》), and *the Expert Consensus on the Diagnosis and Treatment of Influenza in Children* (《兒童流感診斷與治療

專家共識》)。According to data from Menet, the sales revenue of Peramivir-related pharmaceutical products across the three major terminals and six major markets in the PRC exceeded RMB800 million in aggregate in 2025.

“Peramivir Injection” is another important product of the Group, which further enriches the Group’s product pipeline in the anti-infective field. The marketing of this product will provide more treatment options for patients with influenza A or B virus.

By order of the Board
Fusen Pharmaceutical Company Limited
Mr. Cao Zhiming
Chairman and Executive Director

Hong Kong, 26 June 2026

As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors, and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.

* *For identification purposes only.*